Soft tissue repair and regeneration using postpartum-derived cells and cell products
Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.
1. A method of treating a soft tissue defect in a subject by administering to said soft tissue defect in said subject a cell lysate produced by lysing cells of a homogenous human umbilical cord cell population in an amount effective to treat the soft tissue defect, wherein the umbilical cord cell population is isolated from human umbilical cord tissue substantially free of blood, is capable of self-renewal and expansion in culture, has the potential to differentiate, and has the following characteristics:
a) potential for at least 40 doublings in culture;
b) production of CD10, CD13, CD44, CD73, CD90 and HLA-A,B,C;
c) lack of production of CD31, CD34, CD45, CD117, CD141 and HLA-DR, HLA-DP and HLA-DQ;
d) secretes MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1; and
e) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell.
2. The method of claim 1 , wherein the population of cells does not secrete SDF-1alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.
3. The method of claim 1 , wherein treatment of a soft tissue defect includes tissue repair, tissue reconstruction, tissue bulking, cosmetic treatment, tissue augmentation and tissue sealing.
4. The method of claim 1 , wherein the lysate comprises HGF, FGF, IL-8, TIMP1 and BDNF.
5. The method of claim 4 , wherein the lysate further comprises ANG2, HB-EGF, KGF, PDGFbb, VEGF, IL-6, MCP1, TGFa, TIMP2 and HGH.
6. The method of claim 1 , wherein a matrix is added to the cell lysate to form a complex, and the complex is administered to the soft tissue defect in said subject.
7. A method of inducing cell infiltration and tissue formation in a subject by administering a cell lysate matrix complex, wherein the cell lysate is produced by lysing cells of a homogeneous population of human umbilical cord tissue-derived cells, wherein the cell lysate is added to a matrix to form a complex, and wherein the population of umbilical cord tissue-derived cells is isolated from human umbilical cord tissue substantially free of blood, is capable of self-renewal and expansion in culture, has the potential to differentiate, and has the following characteristics:
a) potential for at least 40 doublings in culture;
b) production of CD10, CD13, CD44, CD73, CD90 and HLA-A,B,C;
c) lack of production of CD31, CD34, CD45, CD117, CD141 and HLA-DR, HLA-DP and HLA-DQ;
d) secretes MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1; and
e) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell.
8. The method of claim 7 , wherein the cell population does not secrete SDF-1 alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.
9. The method of claim 7 , wherein the method is effective to achieve at least one of tissue repair, tissue reconstruction, tissue bulking, cosmetic treatment, tissue augmentation and tissue sealing.
10. The method of claim 7 , wherein the lysate comprises HGF, FGF, IL-8, TIMP1 and BDNF.
11. The method of claim 10 , wherein the lysate further comprises ANG2, HB-EGF, KGF, PDGFbb, VEGF, IL-6, MCP1, TGFa, TIMP2 and HGH.
12. A method of treating a soft tissue defect in a subject, comprising administering to said soft tissue defect in said subject a homogeneous population of umbilical cord tissue-derived cells in an amount effective to treat the soft tissue defect, wherein the population of umbilical cord tissue-derived cells is isolated from human umbilical cord tissue substantially free of blood, is capable of self-renewal and expansion in culture, has the potential to differentiate, and has the following characteristics:
a) potential for at least 40 doublings in culture;
b) production of CD10, CD13, CD44, CD73, CD90 and HLA-A,B,C;
c) lack of production of CD31, CD34, CD45, CD117, CD141 and HLA-DR, HLA-DP and HLA-DQ;
d) secretes MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1b, RANTES, and TIMP1; and
e) increased expression of endogenous genes encoding interleukin 8 and reticulon 1 relative to endogenous expression of interleukin 8 and reticulon 1 in a human cell that is a fibroblast, a mesenchymal stem cell, or an ileac crest bone marrow cell.
13. The method of claim 12 , wherein the cell population does not secrete SDF-1 alpha, TGF-beta2, ANG2, PDGFbb, MIP1a, and VEGF.
14. The method of claim 12 , wherein treatment of a soft tissue defect includes tissue repair, tissue reconstruction, tissue bulking, cosmetic treatment, tissue augmentation and tissue sealing.